Glenmark Pharma Q3: Profit, revenue up over 15% as India, North America drive growth

Glenmark Pharmaceuticals Ltdreported a strong operational and financial performance in the third quarter ended December 31, 2025, supported by broad-based growth across key geographies and a sharp improvement

in operating margins.

Net profit rose 15.9% year-on-year to ₹403 crore, while revenue increased 15.1% to ₹3,900 crore. EBITDA surged 45% YoY to ₹868.7 crore, reflecting operating leverage and improved product mix, with margins expanding to 22.3% from 17.7% a year ago.

India continued to outperform, with formulations revenue rising 22.1% YoY to ₹12,986 million, driven by strong traction in core therapies. North America emerged as another key growth engine, with revenue climbing 24.2% YoY to ₹9,706 million, aided by new launches, pipeline progression and out-licensing income related to ISB 2001.

Europe posted steady growth of 9.1% YoY to ₹7,963 million, while Emerging Markets revenue increased 8.4% to ₹8,119 million, supported by the respiratory portfolio and expanding global brands.

Commenting on the performance, Chairman and Managing Director Glenn Saldanha said disciplined execution across markets has kept Glenmark on track to deliver its near-term guidance.

He highlighted improving traction across the innovation portfolio, including RYALTRIS® scaling across markets, WINLEVI® gaining momentum in the UK and Europe, and partnered oncology assets strengthening Glenmark’s presence in high-need therapeutic areas.

Shares of Glenmark Pharmaceuticals closed 2.04% higher at ₹2,026.10 on the NSE ahead of the results.